141 related articles for article (PubMed ID: 8958301)
1. Uterine papillary serous carcinoma evolves via a p53-driven pathway.
Moll UM; Chalas E; Auguste M; Meaney D; Chumas J
Hum Pathol; 1996 Dec; 27(12):1295-300. PubMed ID: 8958301
[TBL] [Abstract][Full Text] [Related]
2. Expression and mutation analysis of the p53 gene in uterine papillary serous carcinoma.
King SA; Adas AA; LiVolsi VA; Takahashi H; Behbakht K; McGovern P; Benjamin I; Rubin SC; Boyd J
Cancer; 1995 Jun; 75(11):2700-5. PubMed ID: 7743473
[TBL] [Abstract][Full Text] [Related]
3. p53 protein overexpression: a strong prognostic factor in uterine papillary serous carcinoma.
Bancher-Todesca D; Gitsch G; Williams KE; Kohlberger P; Neunteufel W; Obermair A; Heinze G; Breitenecker G; Hacker NF
Gynecol Oncol; 1998 Oct; 71(1):59-63. PubMed ID: 9784320
[TBL] [Abstract][Full Text] [Related]
4. Endometrial glandular dysplasia: a newly defined precursor lesion of uterine papillary serous carcinoma. Part I: morphologic features.
Zheng W; Liang SX; Yu H; Rutherford T; Chambers SK; Schwartz PE
Int J Surg Pathol; 2004 Jul; 12(3):207-23. PubMed ID: 15306933
[TBL] [Abstract][Full Text] [Related]
5. p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes.
Zheng W; Cao P; Zheng M; Kramer EE; Godwin TA
Gynecol Oncol; 1996 May; 61(2):167-74. PubMed ID: 8626128
[TBL] [Abstract][Full Text] [Related]
6. Loss of p53 function in uterine papillary serous carcinoma.
Kovalev S; Marchenko ND; Gugliotta BG; Chalas E; Chumas J; Moll UM
Hum Pathol; 1998 Jun; 29(6):613-9. PubMed ID: 9635683
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical comparison of uterine papillary serous and papillary endometrioid carcinoma: clues to pathogenesis.
Demopoulos RI; Mesia AF; Mittal K; Vamvakas E
Int J Gynecol Pathol; 1999 Jul; 18(3):233-7. PubMed ID: 12092593
[TBL] [Abstract][Full Text] [Related]
8. p53 and bcl-2 expression in invasive and pre-invasive uterine papillary serous carcinoma and atrophic endometrium.
Busmanis I; Ho TH; Tan SB; Khoo KS
Ann Acad Med Singap; 2005 Aug; 34(7):421-5. PubMed ID: 16123814
[TBL] [Abstract][Full Text] [Related]
9. p53 immunostaining as a significant adjunct diagnostic method for uterine surface carcinoma: precursor of uterine papillary serous carcinoma.
Zheng W; Khurana R; Farahmand S; Wang Y; Zhang ZF; Felix JC
Am J Surg Pathol; 1998 Dec; 22(12):1463-73. PubMed ID: 9850172
[TBL] [Abstract][Full Text] [Related]
10. Immunocytochemical analysis of uterine papillary serous carcinomas for estrogen and progesterone receptors.
Umpierre SA; Burke TW; Tornos C; Ordonez N; Levenback C; Morris M
Int J Gynecol Pathol; 1994 Apr; 13(2):127-30. PubMed ID: 8005733
[TBL] [Abstract][Full Text] [Related]
11. Patterns of failure after the multimodality treatment of uterine papillary serous carcinoma.
Sood BM; Jones J; Gupta S; Khabele D; Guha C; Runowicz C; Goldberg G; Fields A; Anderson P; Vikram B
Int J Radiat Oncol Biol Phys; 2003 Sep; 57(1):208-16. PubMed ID: 12909235
[TBL] [Abstract][Full Text] [Related]
12. Decreased expression of 14-3-3σ is predictive of poor prognosis for patients with human uterine papillary serous carcinoma.
Suzuki F; Nagase S; Suzuki K; Oba E; Hiroki E; Matsuda Y; Akahira J; Nishigori H; Sugiyama T; Otsuki T; Yoshinaga K; Takano T; Niikura H; Ito K; Sasano H; Yaegashi N
Tohoku J Exp Med; 2013 Nov; 231(3):193-9. PubMed ID: 24201220
[TBL] [Abstract][Full Text] [Related]
13. p27 and cyclin D1 abnormalities in uterine papillary serous carcinoma.
Schmitz MJ; Hendricks DT; Farley J; Taylor RR; Geradts J; Rose GS; Birrer MJ
Gynecol Oncol; 2000 Jun; 77(3):439-45. PubMed ID: 10831356
[TBL] [Abstract][Full Text] [Related]
14. Endometrial carcinoma: the prognostic impact of papillary serous carcinoma (UPSC) in relation to nuclear grade, DNA ploidy and p53 expression.
Nordström B; Strang P; Lindgren A; Bergström R; Tribukait B
Anticancer Res; 1996; 16(2):899-904. PubMed ID: 8687148
[TBL] [Abstract][Full Text] [Related]
15. Is adjuvant therapy necessary for stage IA and IB uterine papillary serous carcinoma and clear cell carcinoma after surgical staging?
Kwon JS; Abrams J; Sugimoto A; Carey MS
Int J Gynecol Cancer; 2008; 18(4):820-4. PubMed ID: 17892450
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature.
Kounelis S; Kapranos N; Kouri E; Coppola D; Papadaki H; Jones MW
Mod Pathol; 2000 Apr; 13(4):379-88. PubMed ID: 10786803
[TBL] [Abstract][Full Text] [Related]
17. Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas.
Wu W; Slomovitz BM; Celestino J; Chung L; Thornton A; Lu KH
Cancer Res; 2003 Oct; 63(19):6195-9. PubMed ID: 14559803
[TBL] [Abstract][Full Text] [Related]
18. Uterine papillary serous, clear cell, and poorly differentiated endometrioid carcinomas: a comparative study.
Greggi S; Mangili G; Scaffa C; Scala F; Losito S; Iodice F; Pisano C; Montoli S; Viganò R; Pirozzi G; Giannarelli D
Int J Gynecol Cancer; 2011 May; 21(4):661-7. PubMed ID: 21412164
[TBL] [Abstract][Full Text] [Related]
19. Uterine Papillary Serous Carcinoma: A Single-Institution Review of 62 Cases.
Black C; Feng A; Bittinger S; Quinn M; Neesham D; McNally O
Int J Gynecol Cancer; 2016 Jan; 26(1):133-40. PubMed ID: 26588230
[TBL] [Abstract][Full Text] [Related]
20. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma.
Slomovitz BM; Broaddus RR; Burke TW; Sneige N; Soliman PT; Wu W; Sun CC; Munsell MF; Gershenson DM; Lu KH
J Clin Oncol; 2004 Aug; 22(15):3126-32. PubMed ID: 15284264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
